Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

ENZYBIOTX

Financiado

Upgrading business potential of Enzybiotx

Since the discovery of penicillin people were living in justified confidence that available antibiotics can cure any bacterial infections. Emerging antibiotic resistance was usually overcome by treatment with new generation of ant... ver más

31/01/2023

ENZYBIOTX

75K€

Presupuesto del proyecto: 75K€

Líder del proyecto

ENZYBIOTX SPOLKA Z OGRANICZONA ODPOWIEDZIALNO... No se ha especificado una descripción o un objeto social para esta compañía.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-01-31

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

HORIZON-EIE-2021-SCALEUP-01-03: Women TechEU

Innovación

Cerrada hace 3 años

0% 100% 100%

1 Participantes

ENZYBIOTX

75.00K€ | Lider

Proyectos interesantes

COMBACTE-NET Combatting Bacterial Resistance in Europe 221M€ Cerrado

ChronosAntibiotics Exploring the bacterial cell cycle to re sensitize antibioti... 3M€ Cerrado

DRIVE-AB DRIVING RE-INVESTMENT IN R&D AND RESPONSIBLE ANTIBIOTIC USE 11M€ Cerrado

EUIN2015-62512 PREPARACION DE LA PROPUESTA ERC: ELUCIDANDO LA RESISTENCIA D... 10K€ Cerrado

AGL2016-75536-P EVALUACION DE LOS BACTERIOFAGOS EN LA TRANSFERENCIA DE GENES... 203K€ Cerrado

PID2019-108643GA-I00 ABORDANDO LA RESISTENCIA ANTIMICROBIANA MEDIANTE ESTRUCTURAS... 85K€ Cerrado

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 8 meses Fecha Inicio: 2022-05-16
Fecha Fin: 2023-01-31

Presupuesto del proyecto 75K€

Descripción del proyecto Since the discovery of penicillin people were living in justified confidence that available antibiotics can cure any bacterial infections. Emerging antibiotic resistance was usually overcome by treatment with new generation of antibiotics, but during last decades bacteria are clearly winning this race. Overuse of antibiotics, particularly in agriculture, and lack of investments in discovery of new antibiotics lead us to situation when increasing number of bacterial infections cannot be cured due to lack of effective remedy. Antibiotic resistance surveillance revealed rising antibiotic resistance around the world. WHO predicts that if no appropriate actions are taken by 2050 antibiotic resistance will be responsible even for 10 mln deaths every year. To address this urgent medical need new antibiotics and alternative methods of combating antibiotic resistant bacteria are needed. One of the new approaches which is getting more and more interests among academic and industrial research groups are enzybiotics, bacteriolytic enzymes that in a very effective and selective way eliminate bacteria, including antibiotic resistant strains, at the same time displaying very low resistance prevalence. Enzybiotx provides a deep-tech platform for tailor made-enzybiotics targeting specific bacteria. Our company has developed the platform for design and generation of new enzybiotcs to target pathogenic bacteria of interest as an answer to the need of alternative antimicrobials development. The company in collaboration with potential clients is able to prepare tailor-made enzybiotics which target pathogens and in collaboration with the client, perform all tests needed to adjust enzyme’s properties to be able to introduce them to the final products. The founders of the company are experienced academics who have gathered unique expertise in isolation and characterisation of new enzybiotics.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores